Taysha Gene Therapies, Inc. (TSHA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.60+0.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Increase revenue from $1.85M in 2026 to higher levels: FY26 rev $1.75M vs $1.85M target.
Taysha advances TSHA-102 clinical development with a shortened timeline. The company aims to improve financial performance despite a net loss of $42.41M in 2026-Q1. Market implied growth is high, with 91.8% over 3 years. Debt issuance provides capital for progress.
Taysha remains loss-making with negative EPS of -$0.44 expected in 2026. Revenue estimates are low at $1.85M for 2026 and $29.7M for 2027, showing limited commercial traction. Litigation and earnings misses add risk to the turnaround.
The market prices in a high growth optionality with implied 3-year growth near 92%. Our fair value is $0.92, reflecting cautious optimism but acknowledging ongoing losses and execution risks.
Breaks if: capital runs low or no further funding available in 2026
Breaks if: TSHA-102 development delays or setbacks occur next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. TSHA is currently loss-making and faces elevated risks, but it operates within a sector that has favorable momentum.
The market appears to have priced in a justified valuation, reflecting a low fragility tier. However, there is an expectations gap suggesting that the market is cautious about TSHA's future performance compared to its peers.
Management is focused on advancing clinical development and maintaining financial resources, which are on track. However, recent financial performance has been weak, and the company has a history of earnings misses, indicating potential challenges ahead.
The long-term thesis hinges on TSHA's ability to meet clinical milestones and maintain commercial readiness. Additionally, broader sector performance and economic conditions, such as job reports, will significantly influence investor sentiment.
The most important moves since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
Yes, our read has strengthened. The advancement of TSHA-102 clinical development supports the company's outlook. Recent FDA feedback reinforces this timeline, which is a positive signal for growth. There are no new threats identified that could weaken this position.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: net loss worsens or remains flat relative to -$42.41M in 2026-Q1
Breaks if: revenue falls below $1.85M in FY26 or fails to grow toward $29.7M in FY27
In the next 1 to 3 years, TSHA's outlook will depend on its execution against key priorities and external market factors. Not investment advice.